Skip to main content

TLR4 maintains Treg-mediated protection against adverse outcomes in a model of hepatic surgical stress.

The Journal of clinical investigation2026-03-03PubMed
Total: 87.0Innovation: 9Impact: 0Rigor: 0Citation: 0

Summary

Human and murine data show that Treg-intrinsic TLR4 signaling activates MyD88–ERK–CREB to support IL-10 production, thereby limiting hepatic ischemia–reperfusion injury. Loss of TLR4 in Tregs abrogates protection, while adoptive WT Tregs or exogenous IL-10 restore hepatoprotection.

Key Findings

  • Lower hepatic Treg abundance correlated with greater injury in patients undergoing hepatic hemangioma resection.
  • Treg-specific Tlr4 knockout exacerbated liver I/R injury; WT but not Tlr4-deficient Tregs conferred protection on adoptive transfer.
  • TLR4 in Tregs drives IL-10 via MyD88/ERK/CREB; exogenous IL-10 rescued dysfunction in Treg-Tlr4−/− mice.

Clinical Implications

Targets such as TLR4 on Tregs or downstream IL-10 signaling could be explored to reduce hepatic ischemia–reperfusion injury risk in liver surgery and transplantation.

Why It Matters

Reveals a tractable immunoregulatory axis for perioperative organ protection with direct mechanistic evidence and translational relevance to liver surgery.

Limitations

  • Primary efficacy shown in murine I/R models; clinical efficacy and safety of immunomodulation remain untested.
  • Potential context-specific effects of TLR4 signaling and IL-10 may complicate translation.

Future Directions

Evaluate perioperative strategies to enhance Treg TLR4–IL-10 signaling (e.g., Treg expansion, targeted agonism, IL-10 delivery) and validate biomarkers of response in liver surgery patients.

Study Information

Study Type
Case series
Research Domain
Pathophysiology
Evidence Level
V - Preclinical mechanistic study with human correlative observations; hypothesis-generating.
Study Design
OTHER